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Heparin does not cross the placenta and is therefore
not responsible for the fetal effects that warfarin poses.
However, concern exists primarily in two other areas.
First, long-term use may be impractical and require long-
term nursing care for administration of subcutaneous dos-
ing. Second, an overall concern exists about the potential
for bleeding during delivery while patients are being anti-
coagulated with heparin. In addition, its long-term use
may be associated with alopecia, osteoporosis, and neuro-
logic complications.12,13
The use of inferior vena cava filters during pregnancy
has been described in isolated case reports in the English
medical literature.8-11,14-17 This study reviews our experi-
ence in the placement of Greenfield inferior vena cava fil-
ters in pregnant patients with DVT of the lower extremity,
for both therapeutic indications and prophylaxis in
patients who have iliofemoral DVT in the last month of
pregnancy. Filters were placed in these patients, who may
have a higher risk of developing pulmonary embolism
once heparin is discontinued before active labor, and in
patients who have a fear of heparin complications.
PATIENT POPULATIONS AND METHODS
Eighteen pregnant patients who had DVT of the lower
extremity, pulmonary embolism, or both and had
Greenfield filters placed during pregnancy in the last 12
years (1987-1998) were identified, and their medical
Deep venous thrombosis (DVT) and subsequent pul-
monary embolism are serious complications of pregnancy.
Several studies have identified pulmonary embolism as one
of the most common causes of maternal deaths.1-3 The
choice of treatment options for DVT of the lower extrem-
ity during pregnancy remains controversial.4-14
The pharmacologic treatments have their inherent
problems.4,5 When given during the first trimester of
pregnancy, warfarin therapy has been associated with an
embryopathy. Malformations, especially those of the cen-
tral nervous system, have been linked to warfarin through-
out the gestational period. In addition, warfarin is
associated with a significant proportion of fetal deaths,
most often from fetal hemorrhage. It is uniformly con-
traindicated for use in pregnancy (category X) and is,
therefore, not an option in the treatment of DVT.4
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Endovascular caval interruption in pregnant
patients with deep vein thrombosis of the
lower extremity
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Purpose: The choice of therapy for deep vein thrombosis (DVT) of the lower extremity during pregnancy has been
widely debated. Warfarin passes through the placenta to the fetus and may cause fetal complications and/or death.
Heparin, in contrast, does not cross the placenta, but its long-term use may be impractical and may increase the risk of
bleeding, osteoporosis, and neurologic complications. The use of inferior vena cava filters in pregnancy has only been
described as case reports in the English medical literature; therefore, this study reviews our experience on this subject.
Methods: We analyzed 18 pregnant patients who had Greenfield filters (GFs) inserted for DVT of the lower extremity,
pulmonary embolism (PE), or both. The DVT diagnosis was made by means of duplex imaging. Conventional full-dose
intravenous heparin was initiated until the filter was inserted, followed by subcutaneous heparin until labor, and con-
tinued for 6 weeks postpartum in 13 patients who were breast-feeding. Warfarin was given postpartum in the other
five patients.
Results: The mean age of the patients was 25 years. The indications for GF insertion included 3 patients who had a PE
while on anticoagulation, 2 patients with significant bleeding caused by anticoagulation, 4 patients with free-floating
iliofemoral DVT, 2 patients with heparin-induced thrombocytopenia, and 7 patients with iliofemoropopliteal DVT
occurring 1 to 3 weeks before labor, for prophylactic reasons. Fourteen of 18 cases were diagnosed in the third
trimester of the patient’s pregnancy. Filters were inserted via the right internal jugular vein by means of a cut-down
technique in the first four patients (stainless steel filters) and percutaneously in 14 patients. The mean fluoroscopy time
during filter insertion was less than 2 minutes. There was no fetal or maternal morbidity or mortality. During long-
term follow-up (mean, 78 months), no PE or filter-related complications were encountered.
Conclusion: GF insertion in pregnant patients with DVT of the lower extremity is safe and effective. Its prophylactic use in
pregnant patients who have extensive iliofemoral DVT right before labor may be justified. (J Vasc Surg 2001;33:375-8.)
records were analyzed. All pertinent clinical data were col-
lected, including a past history of DVT and pulmonary
embolism, number of past pregnancies and deliveries, and
use of birth control pills. All coagulation study results,
including protein C, protein S, antithrombin III, lupus anti-
coagulant antibodies, anticardiolipin antibodies, and factor
V Leiden were reported, if completed. All 18 patients were
symptomatic at their initial presentation, and the clinical
diagnosis was confirmed with duplex ultrasonography.
All patients were initially treated with conventional
therapy consisting of continuous full-dose intravenous
heparin (5000-10,000 units intravenous bolus; then the
dosage was adjusted by an activated partial thromboplas-
tin time of 1.5 to 2.5 of the control) until the inferior vena
cava filter was inserted. This was followed by subcuta-
neous heparin, and the dosage was adjusted to keep an
activated partial thromboplastin time of approximately 1.5
to 2 times the control until labor, if there was no con-
traindication to heparin therapy. Heparin was held when
active labor commenced and restarted as soon as possible
after delivery. In two patients with iliofemoral DVT who
were 2 to 3 weeks from delivery and who feared the risk
of full-dose heparin therapy, filters were inserted for pul-
monary embolism prophylaxis, followed by administration
of 5000 units of heparin subcutaneously every 12 hours
until labor began, for prophylactic reasons only. The two
patients who had heparin-induced thrombocytopenia
were not given heparin after this diagnosis was established.
After delivery, 13 lactating patients were given 5000 units
of subcutaneous heparin every 12 hours, and the other five
patients, who were not lactating, were given 5 mg of war-
farin (Coumadin) daily for 6 to 8 weeks. All patients were
treated with bed rest and leg elevation until the acute
swelling was resolved. Prescription support stockings were
used during ambulation.
All patients were examined for evidence of residual leg
swelling or other symptoms and signs of chronic venous
insufficiency. They also underwent venous duplex imaging
as a means of assessing the resolution of the DVT. In all
patients, abdominal radiographs were taken to check the
level of their filters during their last follow-up. Also, every
effort was made to comply with the consensus reporting
standards for venous disease.18
RESULTS
The mean age of the 18 patients included in this series
was 25 years (range, 19-31 years). The follow-up period
ranged from 10 to 142 months, with a mean of 78 months.
There were no risk factors for DVT, except pregnancy (risk
factor score, 1), in 12 patients. One patient had a past his-
tory of proven DVT (total risk factor score, 3), and four
patients had proven untreated prethrombotic states (total
risk factor score, 4: 3 for prethrombotic state and 1 for
pregnancy). Twelve patients underwent special coagulation
studies; however, only 4 patients had positive study results:
2 patients had protein S deficiencies, 1 patient had an
antithrombin III deficiency, and 1 patient had a protein C
deficiency. Thirteen of the 18 cases occurred in the left
lower extremity. The location of the venous thrombosis
was iliofemoropopliteal in 14 cases (these involved more
than 1 segment, iliofemoral and femoropopliteal) and
femoropopliteal in four cases. Fourteen of 18 cases were
diagnosed in the third trimester of the patient’s pregnancy,
3 cases were diagnosed in the second trimester, and 1 case
was diagnosed in the first trimester.
The indications for Greenfield filter insertion included
3 patients with pulmonary embolism who were receiving
therapeutic anticoagulation, 2 patients with significant
bleeding caused by anticoagulation, 4 patients with free-
floating iliofemoral DVT, 2 patients with heparin-induced
thrombocytopenia, and 7 patients with iliofemoral
popliteal DVT occurring 1 to 3 weeks before labor, for
prophylactic reasons. The DVT progressed from
femoropopliteal to iliofemoral DVT in three of these seven
patients. These seven patients had Greenfield filters
inserted to avoid hemorrhage from full anticoagulation
during labor and pulmonary embolism during the stress of
delivery, when the heparin is being discontinued.
The Greenfield filters were inserted via the right inter-
nal jugular vein in each patient. The first four filters were
made of stainless steel and were placed by means of a cut-
down technique. The remaining 14 filters were placed per-
cutaneously. Eleven of these were made of titanium, and
three were made of the new stainless steel. Ten of these fil-
ters were inserted just below the level of the renal vein,
and eight filters were inserted suprarenally. All filters were
inserted by means of fluoroscopic examination with
shielding of the uterus. The mean fluoroscopic time dur-
ing filter insertion was less than 2 minutes. There was no
perioperative fetal or maternal morbidity or mortality.
During the long-term follow-up period (mean, 78
months), no pulmonary embolism or filter-related compli-
cations were encountered. Fourteen patients were asymp-
tomatic (COA), and 4 of 18 patients had significant leg
swelling (C3-6s) caused by partial resolution of DVT, with
venous reflux in 2 patients and total venous occlusion in 2
patients (iliofemoral occlusion), as documented by means
of venous duplex ultrasound scanning/venography, and
were treated conservatively (long-term anticoagulation
and compression stockings).
DISCUSSION
Thromboembolism is an uncommon problem
encountered during pregnancy and the postpartum
period, but its complications, such as pulmonary
embolism, are often life threatening. Once a diagnosis of
DVT is made, treatment needs to be initiated immediately.
Although heparin remains the treatment of choice for
DVT during pregnancy, it may not be feasible or safe to
initiate or continue anticoagulation in certain pregnant
patients. The use of inferior vena cava filters during preg-
nancy has been reported to be safe and effective, but it has
only been described in isolated case reports in the English
medical literature.8-11,14-17 The general indications for
inferior vena cava interruption in the treatment of DVT or
pulmonary embolism during pregnancy are similar to the
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indications in patients who are not pregnant. As in
patients who are not pregnant, the use of inferior vena
cava filters is recommended in patients with confirmed
DVT or pulmonary embolism with a contraindication to
or complication with heparin therapy15 or recurrence of
pulmonary embolism in spite of adequate anticoagula-
tion.10 Placenta previa or retained placenta carries a high
risk of bleeding with heparin therapy, and these conditions
can be indications for inferior vena cava filter insertion.
Other relative indications include a free-floating thrombus
documented by means of duplex examination and the
presence of extensive iliac thrombosis that may confer a
high risk of pulmonary embolism.11,16 Another potential
prophylactic indication is prevention of pulmonary
embolism in pregnant patients with iliofemoral DVT, who
are near the time of labor (within 2-3 weeks), because
heparin is held once labor starts. This procedure was con-
ducted in seven patients in our series.
In our series, there was no perioperative morbidity or
mortality associated with the procedure, and each patient
tolerated the procedure well. In a long-term follow-up
period (mean, 78 months), there were no filter-related
complications in this series. In addition to no maternal
complications, there were also no fetal complications with
Greenfield filter placement. Several authorities recom-
mend the suprarenal inferior vena cava filter placement to
prevent a pulmonary embolism via the left ovarian
vein.8,19,20 This was done in eight of our patients. As indi-
cated, the 13 lactating patients were given subcutaneous
heparin instead of oral anticoagulation after delivery
because of the potentiation, particularly in the puer-
perium, of a wide variety of medications such as tranquil-
izers, sedatives, and antibiotics that may be used and that
can modify the metabolism of warfarin drugs.21 However,
these patients could have been treated with Coumadin,
because the breakdown by-product that can be detected in
breast milk does not have any anticoagulant properties.
Fluoroscopy, which is necessary for the procedure, was
only used briefly (less than 2 minutes for each patient). It
has been estimated that 2 minutes of fluoroscopy to the
abdomen exposes the area to only 0.5 rad of irradiation,
which is within the safety limit of fetal exposure.22 Most
authorities recommend the use of duplex ultrasound as a
means of diagnosis of DVT in pregnancy to minimize the
potential risk of radiation from phlebography, which may
have the associated risk of exposing the fetus to radiation.
However, the radiation has been calculated to be minimal
with abdominal shielding (a dose of < 0.05 rad).23 Ginsberg
et al23 calculated levels of radiation exposure to the fetus for
common diagnostic procedures and conducted a literature
review to examine the fetal risks associated with these levels
of radiation. A small increase in the relative risk of childhood
cancer was suggested by a literature review of outcomes
after low-dose (< 5 rad), in utero radiation exposure. They
concluded that, with careful use of the available procedures,
a diagnosis of venous thrombosis is possible with fetal radi-
ation exposure of less than 0.50 rad, and a diagnosis of pul-
monary embolism is possible with fetal radiation exposure
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of less than 0.05 rad. The risk of such exposure is small,
both in relative and absolute terms.
Several studies reported on the successful use of both
intravascular ultrasound scanning and external duplex ultra-
sound scanning in vena cava filter placement. These tech-
niques will eliminate the need for fluoroscopy during
pregnancy, thereby avoiding fetal exposure to irradiation.24-26
Recently, several studies have reported on the safety of
the use of low-molecular weight heparin in pregnancy.27-31
Low-molecular weight heparin is an attractive alternative to
unfractionated heparin, because of its association with a
lower incidence of osteoporosis and heparin-induced throm-
bocytopenia and possibly less bleeding. Low-molecular
weight heparin has been recommended for both DVT pro-
phylaxis and treatment for venous thromboembolism during
pregnancy. It is attractive for the long-term management of
DVT in pregnant patients, because it lacks teratogenic prop-
erties, does not penetrate the placenta, and is detected at
negligible levels in the maternal milk, with minimal side
effects to the mother or fetus.27-31
Enson and Stevenson31 conducted a systematic review
with Medline and Cochrane Library data base searches and
a bibliography review of English-language reports describing
therapy with low-molecular weight heparin in pregnancy.
They concluded that the published experience suggested
that low-molecular weight heparin is generally safe and effec-
tive when administered for thromboprophylaxis during
pregnancy. They also concluded that until prospective, ran-
domized, controlled trials comparing low-molecular weight
heparin with unfractionated heparin are performed, the ben-
efits during pregnancy still remain inconclusive.
CONCLUSION
Greenfield filter insertion in pregnant patients with DVT
of the lower extremity or pulmonary embolism is safe and
effective. Its prophylactic use in certain pregnant patients
who have iliofemoral DVT close to labor may be justified.
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